Fennec swings to FY26 Q2 net income of $1.97 million; net sales rise 78% to $17.1 million year over year

Reuters2026/08/11 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fennec reported Q2 2026 net sales of USD 17.1 million, up 78% year over year.
GAAP net income turned to USD 2 million, or USD 0.06 per share.
Non-GAAP adjusted EBITDA swung to USD 2.8 million.
Selling and marketing expense climbed to USD 10.7 million as it expanded its sales organization and PEDMARK awareness initiatives.
Management cited record PEDMARK demand carrying into Q3 as field sales expansion continues; ASCO 2026 data supported integration without compromising cisplatin activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110701PRIMZONEFULLFEED9807240) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fennec swings to FY26 Q2 net income of $1.97 million; net sales rise 78% to $17.1 million year over year

You may also like

Crypto prices